Dear Friends:

As cancer research moved to the forefront of the national consciousness over the last year, the Lymphoma Research Foundation (LRF) was able to answer the challenge for an increase to evidence-based research in 2016.

Throughout the year, members of the LRF Scientific Advisory Board played integral roles in steering global research policy, developing game-changing imaging and diagnostic techniques, and publishing key findings in the developing study of immuno-therapy and precision medicine. Your support of these initiatives enabled LRF to create and foster an ecosystem of investment in today’s most promising research; research that will advance our mission to eradicate lymphoma and serve those impacted by this blood cancer.

We believe that today’s research will lead to tomorrow’s cures, as evidenced by the more than a half-dozen new lymphoma drug indications approved by the FDA in 2016, many of which were for lymphoma subtypes with no previous treatment indications. The Lymphoma Research Foundation was proud to witness members of our scientific community paving the way for these critical advancements.

The Lymphoma Research Foundation once again reaffirmed its unique commitment to early career investigators as well, ensuring that these talented researchers are able to pursue the future of discovery. In keeping with that philosophy, another LCRMP Scholar Anita Kumar, MD, Memorial Sloan Kettering Cancer Center, discovered new ways to identify specific Hodgkin lymphoma patients who may be in need of more aggressive treatment. LRF Scientific Advisory Board Member Ash Alizadeh, MD, PhD, Stanford School of Medicine, and Lymphoma Clinical Research Mentoring Program (LCRMP) Scholar David Kurtz, MD, Stanford School of Medicine, published key findings on the discovery of genetic subtypes of diffuse large B-cell lymphoma (DLBCL) without the need for invasive biopsies.

As the Lymphoma Research Foundation continues to grow in its reach and impact, we thank our generous donors, volunteers and partners, without whom our ability to serve the blood cancer community would be impossible. We remain steadfast in advancing our mission and we are confident that with your continued support, we will be able to cure lymphoma within our lifetime.

Michael Werner
Chair
LRF Board of Directors

Meghan Gutierrez
CEO
Lymphoma Research Foundation
2016 witnessed a historic shift in the national conversation around oncology research, and the demand for a cure became more immediate than ever before. Cancer research was pushed to the forefront of the national dialogue on January 12, when President Barack Obama issued a challenge to the nation’s research community to end cancer within our lifetime, effectively accelerating the clock on a cure in the form of the Cancer Moonshot.

This timely and critical challenge demanded an understanding that the idea of a cure will need to take many forms in order to address the nuanced nature of each cancer diagnosis, as is most evident in hematological malignancies including lymphoma.

“So tonight, I’m announcing a new national effort to get it done,” said President Obama. “Medical research is critical.”

With that, President Obama brought into the national spotlight the work that the nation’s researchers, patient advocates, pharmaceutical industry, and organizations like the Lymphoma Research Foundation have been consistently undertaking on behalf of all cancer patients. According to the National Cancer Institute, 39.6 percent of Americans will develop some form of cancer during their lifetime, yet treatments remain unavailable for many cancer types.

Pursuit of new therapies and cures will only be realized through greater investment in cancer research.

Following the announcement of the Moonshot, the Lymphoma Research Foundation was able to take part in and lead several critical aspects of the Initiative. LRF Scientific Advisory Board (SAB) member Andrew Evens, MD, Chief of Hematology/Oncology and Director of the Tufts Cancer Center, was among the first researchers selected to advise Vice President Joe Biden as a part of the Moonshot. The Lymphoma Research Foundation was proud to have a Scientific Advisory Board member participate in key discussions to ensure that the voice of the lymphoma community was not only heard, but was foundational to the Moonshot.

In response to the President’s national challenge, the Lymphoma Research Foundation brought together members of Congress, lymphoma researchers and clinicians, industry partners, patients, and members of the nonprofit sector for a special Capitol Hill briefing for U.S. federal policy makers on March 22 entitled “Tackling Adolescent and Young Adult (AYA) Lymphoma.”

A part of the Foundation’s #EraseLymphoma initiative, this event helped highlight the unique challenges that adolescents and young adults with cancer face and sought to address clinical gaps that exist for this population.

Three months later, on June 29, the Lymphoma Research Foundation hosted a national roundtable discussion on the Cancer Moonshot, outlining the vision for LRF’s role in creating new public and private partnerships, investment strategies for the most promising areas of lymphoma and CLL research, research data collaboration, and national healthcare access. The roundtable helped to answer questions on the Moonshot’s direct impact on lymphoma research, and provided a forum for the Lymphoma Research Foundation to further align its policy priorities with the needs of the patient and caregiver community.

The Lymphoma Research Foundation continued to serve as a critical driver of an increasingly aggressive national research agenda throughout the year, by virtue of its scientific expertise and role as a public policy thought leader. These efforts culminated in a meeting in early 2017 between Vice President Joe Biden, LRF Chief Executive Officer Meghan Gutierrez, and other industry and nonprofit partners to further our collaborative effort to shape a research-friendly policy environment for the future.
For decades, many cancer treatments had been designed around a “one-size-fits-all” approach, which can be successful for some patients, but not for others. The treatment of lymphomas, by contrast, has been at the forefront of precision medicine for decades. Given the heterogeneity of blood cancers, a diverse treatment approach and understanding of each lymphoma subtype have been hallmarks of the investigation and pursuit of new therapies. In fact, the concept of delivering targeted treatments to patients in many regards began in lymphoma patients.

The Lymphoma Research Foundation sought to leverage the unique complexities of lymphoma to support more individualized approaches throughout 2016, in an effort to help foster the best clinical outcomes for today’s lymphoma community.

The Lymphoma Research Foundation has been proud to be a leader in furthering the understanding of the complexities of lymphoma—laying the foundation for specialized treatment based upon specific characteristics of a patient’s disease. The growing area of study around genetics and their ability to identify certain biomarkers in an individual that can be used to determine prognosis as well as treatment pathways may help improve outcomes for patients whose options have been historically limited. In an effort to ensure patients and their loved ones have access to all of the latest information regarding their disease, the Lymphoma Research Foundation’s 2016 educational programs included information on genetic testing.

Additionally, the Foundation launched its latest disease-specific website, Focus on Diffuse Large B-Cell Lymphoma (FocusOnDLBCL.org) which includes in-depth information on diagnostics and genetic testing as a critical factor in the diagnosis and treatment of DLBCL patients.

In keeping with this tradition of further advancing precision medicine, Lymphoma Research Foundation Grantee and Lymphoma Clinical Research Mentoring Program (LCRMP) Scholar, Anita Kumar, MD, Memorial Sloan Kettering Cancer Center, published a study in Haematologica in the summer of 2016, which analyzed the prognostic significance of Hodgkin lymphoma tumor size in the era of improved computerized tomography (CT) imaging—allowing for measurement of the tumor in multiple dimensions. This unique study allowed doctors to identify specific Hodgkin lymphoma patients who may be in need of more aggressive treatment.

In the winter of 2016, Ash Alizadeh, MD, PhD, Stanford School of Medicine, Member of the LRF Scientific Advisory Board and past LRF Grantee and LCRMP Scholar David Kurtz, MD, Stanford School of Medicine, published a first-of-its-kind study which demonstrated circulating tumor DNA (ctDNA) and its ability to reveal distinct genetic subtypes of diffuse large B-cell lymphoma (DLBCL) without the need for invasive procedures like a tumor biopsy. Reducing the need for potentially painful procedures such as these by utilizing the understanding of the genetic characteristics of tumor cells enables physicians to administer targeted therapies with as little negative impact on the daily lives of lymphoma patients as possible. This discovery proved especially important in light of recent studies showing that various lymphoma therapies have different outcomes based on DLBCL subtypes.

By investing in early career scientists and forward-thinking lymphoma researchers like Drs. Alizadeh, Kurtz and Kumar, the Lymphoma Research Foundation demonstrated its leadership and commitment to advancing the most promising research that has the most potential to deliver more individualized and targeted treatments to lymphoma patients. The Foundation remains committed to ensuring that the right patients have access to the right treatments at the right time.

“As our understanding of the subtleties of the precise genetic mutations of DNA continue to evolve, we can greatly reduce the need for invasive biopsies in our patients, and LRF’s research is geared towards leveraging these types of discoveries to the benefit of all.”

— Ash Alizadeh, MD, PhD
Stanford School of Medicine
Member, Lymphoma Research Foundation’s Scientific Advisory Board
Past LRF Grantee
The burgeoning study of immunotherapy revolves around harnessing and enhancing the innate powers of the immune system to fight cancer. While the idea of immunotherapy has been a part of lymphoma treatment for many years with treatment options such as rituximab (Rituxan), this new approach may represent the greatest promise for chemotherapy-free treatments in decades, and has been considered one of the biggest breakthroughs in cancer treatment since the development of the first chemotherapies in the late 1940’s.

To ensure that patients understand this emerging new treatment paradigm and its practical use in lymphoma, the Lymphoma Research Foundation launched an immunotherapy pilot program for lymphoma patients, survivors and their loved ones in 2016. Recognizing that patients learn and digest information in different ways, this educational program consisted of live in-person programs, including a dedicated seminar at the Lymphoma Research Foundation’s Annual North American Educational Forum on Lymphoma, and an Advances in Immunotherapy in the Treatment of Lymphoma teleconference.

In early 2017, the Foundation also debuted a dedicated immunotherapy fact sheet and a video on immunotherapy for the treatment of lymphoma. The Foundation assessed people’s understanding of immunotherapy in lymphoma before and after utilizing each educational resource to determine gaps in understanding, as well as to determine the best modes of education.

Throughout 2016, LRF continued to provide the lymphoma community with the latest information on lymphoma research and treatment. In an effort to serve new patient communities throughout the country, the Lymphoma Research Foundation hosted over 2,500 individuals at LRF’s in-person education programs, received over 10,000 inquiries to its Lymphoma Helpline, and reached an additional million patients and caregivers through digital educational resources last year.

The Lymphoma Research Foundation’s commitment to education extends beyond direct patient outreach to professional education for oncologists and nurses—both in academic and in community centers. In light of the accelerated developments around immunotherapy, the Lymphoma Research Foundation utilized its professional education series, Lymphoma Rounds, as a platform for scientific discourse around immunotherapy as a treatment option for lymphoma patients. LRF’s 2016 Lymphoma Rounds series provided an opportunity for health care professionals to discuss lymphoma cases in a collaborative environment to increase their knowledge of immunotherapy in order to ultimately improve the quality of care for all lymphoma patients.

In September 2016, the Lymphoma Research Foundation hosted its first-ever Lymphoma Rounds Summit program which featured a case study by Stephen J. Schuster, MD, Director, Lymphoma Program Hospital of the University of Pennsylvania.

“Immunotherapy is an incredibly exciting treatment option for many types of cancer, and particularly for specific subtypes of lymphoma. When clinically appropriate, the ability to enhance a patient’s own immune response against cancer, as we do with CAR T-cell therapy, could decrease patients’ toxicities from treatment and potentially increase the efficacy of treatment for all cancers, including lymphomas.”

— Stephen J. Schuster, MD
Director, Lymphoma Program
Hospital of the University of Pennsylvania
Innovative Ideas

Supporting The Future of Lymphoma Research

The Lymphoma Research Foundation recognizes that the next generation of lymphoma researchers will be faced with increasingly serious challenges due to the impact of limited grant funding and the evolving research and treatment landscape. Young scientists around the world have highlighted the importance of having mentors and a support system to advise them on their career trajectory and determining which area of research they should pursue. The Lymphoma Research Foundation believes it is critical to support early career scientists and promote their involvement in the greater lymphoma research community and the LRF mission.

In 2016, the Lymphoma Research Foundation took its commitment to ensuring that the best and brightest minds remain dedicated to lymphoma research to the next level, funding over 40,000 research hours for early career lymphoma scientists. LRF understands the importance of funding young investigators who have the greatest capacity for innovation in the study of today’s and tomorrow’s most promising therapies.

These investments in young scientists include Pilar Dominguez Rodriguez, PhD, Weill Cornell Medicine’s LRF Postdoctoral Fellowship Grant on identifying new potential targets for DLBCL therapies based on established genetic markers and David Hon Quach, PhD, Baylor University Medical Center’s LRF Postdoctoral Fellowship Grant on making CAR T-cell immunotherapy more accessible as a standard treatment option by preventing the patients’ immune systems from rejecting donor cells. These are just two of the promising grants within the Lymphoma Research Foundation’s research portfolio that are carefully engineered to improve outcomes for today’s lymphoma community.

In keeping with the organization’s unique commitment to ensuring that early-stage scientists are able not only to explore the most promising new research models, but also to leverage the breadth of knowledge from members of the Lymphoma Research Foundation’s industry-leading Scientific Advisory Board, LRF welcomed its third annual class of LRF Scholars—participants in the Lymphoma Clinical Research Mentoring Program (LCRMP) in 2016.

As recipients of the organization’s flagship Young Investigator Grant program, these six early-career scientists have all been identified by the SAB as some of the most promising young minds in the field of hematology research and were selected based on their potential to change the game for lymphoma patients and their families in the future.

This potential was soon realized, as three LRF Scholars were selected to present findings at last year’s annual Congress of the European Hematology Association (EHA). The Scholars, some in their very first year of funding, were able to present their research—directly resulting from Lymphoma Research Foundation funding—to the world’s preeminent hematologists at what is widely regarded as the premier blood cancer conference in Europe.

In 2015, Scholar Danielle Brander, MD, Duke University, presented a study on new combinations of drugs to improve outcomes for CLL/SLL patients. Fellow 2015 Scholar Carla Casulo, MD, University of Rochester, presented preliminary results evaluating the safety and efficacy of additional novel combinations in untreated CD20+ follicular lymphoma. Alex F. Herrera, MD, City of Hope, a 2016 Scholar, presented a study evaluating the prognostic impact of double-hit (DHL) and double-expression (DEL) in DLBCL patients who undergo stem cell transplantation.

These wide-ranging presentations highlighted the innovative thinking of LRF Scholars in various areas of hematology research and further established their role in the future of the lymphoma landscape.

With 17 institutions from the U.S. and abroad represented by the 20 Scholars of the LCRMP’s first three years, the Lymphoma Research Foundation’s national and international footprint as the premier organization for the funding of young blood cancer researchers was further cemented at this year’s American Society of Hematology Annual Meeting in December 2016. The 58th ASH Annual meeting provided a critical forum for leading hematologists and oncologists to present their findings to over 20,000 of their peers.

“As our thinking around the treatment of lymphoma continues to evolve, we need a new way of looking at toxicity and the impact that has on the patient and their family. The funds and mentorship provided as part of the Lymphoma Research Foundation’s Clinical Research Mentoring Program enables me to focus on the individual, so that we can one day bring about a new, and improved, way to treat lymphoma patients.”

— Gita Thanarajasingam, MD
Mayo Clinic, Rochester
Lymphoma Clinical Research Mentoring Program Participant
Lymphoma Community

Meeting Today’s Needs

Even with the announcement of the Cancer Moonshot as a national policy priority, only one-in-ten federal research grants are currently funded by the government each year. As a result, the Lymphoma Research Foundation’s fundraising and awareness events are critical to providing hope to those affected by a lymphoma diagnosis, and to driving research revenue to advance the potential for cures.

In keeping with the Lymphoma Research Foundation’s dual mission of eradicating lymphoma and serving those touched by this blood cancer, LRF invested $1.67 million in lymphoma and serving those touched by this blood cancer, LRF invested $1.67 million in lymphoma-specific research grants in FY 2016, and expanded its grant funding capacities through several key fundraisers throughout the year. LRF’s distinguished events brought in nearly $2 million in support of LRF’s innovative research programs and mission. To that end, LRF’s distinguished events team expanded the national Swirl: A Wine Tasting Event series to new markets to increase LRF’s funding impact.

On September 25, 2016 (Q1 FY17), over 360 cyclists from all across the country participated in the 10th Annual Lymphoma Research Ride. The 10th anniversary event brought the fundraising total of the Research Ride to more than $4.5 million in support of LRF’s mission over the last decade and drew praise from Maryland’s Governor Larry Hogan, a non-Hodgkin lymphoma survivor.

“Your selfless efforts mean a lot to me personally,” said Governor Hogan in an official statement. “I would like to thank the Lymphoma Research Foundation, today’s event planners and participants, and everyone else whose support and dedication has raised public awareness for lymphoma and the funds needed to help fight it.”

LRF’s national awareness initiatives also took major steps forward in 2016, reaching more individuals through its innovative campaigns than ever before. Among these, the Lymphoma Research Foundation further developed its strategic cause marketing campaigns in FY 2016, including partnerships with Southern Glazer’s Wine and Spirits, Neiman Marcus Boca Ratten, and Hy-Vee Supermarkets.

In an effort to further increase national awareness around September’s Blood Cancer Awareness Month, LRF partnered with more than 60 national and international landmarks to light red on World Lymphoma Awareness Day (WLAD – September 15th in honor of WLAD). These efforts, combined with the 2016 Annual Gala which brought in over $1 million during BCAM 2016 (Q1 FY17), raised critical research funds and increased awareness among millions of people in the process.

Raising awareness in an effort to drive funding for evidence-based research and exceptional patient education are critical to finding a cure for lymphoma, and last year saw the Lymphoma Research Foundation bring together the blood cancer community in new and exciting ways to increase LRF’s potential for impact.

“In an extremely exciting time for the Lymphoma Research Foundation and its mission. New events like Swirl: Chicago and Swirl: New York are enabling us to raise critical funds and awareness, helping us to broaden our impact on the lymphoma community.”

— Joe Ferraro

Member, LRF Board of Directors

Host Committee Member Swirl: A Wine Tasting Event – Chicago

Pictured above with his mother, Jean Ferraro
The Condensed Balance Sheets and Statements of Activities of the Lymphoma Research Foundation as of June 30, 2016 and 2015 have been derived from LRF’s audited financial statements. The Lymphoma Research Foundation’s complete set of audited financial statements and related information can be found on the Lymphoma Research Foundation’s website, lymphoma.org/annual report. The Financial Statements have been audited by KPMG LLP.
When I was first diagnosed with lymphoma, I was overwhelmed. But then I found the Lymphoma Research Foundation. The support and resources that LRF provided my family and me was a critical factor in helping me make the best decisions for my treatment. Now, as a member of LRF’s Board of Directors, I am committed to helping LRF further its impact so that others can benefit from their exceptional educational offerings, and perhaps most importantly, so that we can fund researchers - including, we hope, the ones who will discover a cure for lymphoma in my lifetime.

— Tom Goldstone
Member, LRF Board of Directors
Pictured above with wife, Jenn Goldstone
The Lymphoma Research Foundation’s volunteer Scientific Advisory Board, comprised of 45 world-renowned lymphoma experts, guides the Foundation’s research activities, seeking out the most innovative and promising lymphoma research projects for support.
There is a common thread among countless researchers on the forefront of today’s blood cancer research landscape: their direct involvement with the Lymphoma Research Foundation and its Scientific Advisory Board. LRF’s prominence as a critical enabler of research in the hematology space is clear, and I have no doubt that their innovative approach to research funding will help bring us closer to a cure.

— Thomas M. Habermann, MD
Mayo Clinic, Rochester
LRF Scientific Advisory Board Chair Elect

Pictured above with Leigh Olson, Member, LRF Board of Directors

<table>
<thead>
<tr>
<th>Individual, Estate and Foundation Donors</th>
<th>Fiscal Year 2016 (July 1, 2015–June 30, 2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$100,000+</strong></td>
<td>Caroline’s Kids Foundation</td>
</tr>
<tr>
<td></td>
<td>The Jerome and Elaine Nerenberg</td>
</tr>
<tr>
<td></td>
<td>Foundation</td>
</tr>
<tr>
<td></td>
<td>Prince Family Foundation</td>
</tr>
<tr>
<td><strong>$50,000 to $99,999</strong></td>
<td>The Cordon Family Foundation</td>
</tr>
<tr>
<td></td>
<td>Trisha and Chuck Elcan</td>
</tr>
<tr>
<td></td>
<td>Frank M. Ewing Foundation, Inc.</td>
</tr>
<tr>
<td></td>
<td>Estate of Rita Hertzig</td>
</tr>
<tr>
<td></td>
<td>The Thomas J. Keys Living Trust</td>
</tr>
<tr>
<td></td>
<td>The Paul Foundation</td>
</tr>
<tr>
<td></td>
<td>Leigh and Cory Olson</td>
</tr>
<tr>
<td></td>
<td>Lois and Jerry Rosenblum</td>
</tr>
<tr>
<td></td>
<td>The John and Louise Steegstra Memorial</td>
</tr>
<tr>
<td></td>
<td>Fund</td>
</tr>
<tr>
<td></td>
<td>Jane and James Stern</td>
</tr>
<tr>
<td></td>
<td>The Werner Family</td>
</tr>
<tr>
<td><strong>$25,000 to $49,000</strong></td>
<td>Gladys and Errol Cook</td>
</tr>
<tr>
<td></td>
<td>Arlene and Robert Fischer/</td>
</tr>
<tr>
<td></td>
<td>Daroiger Foundation, Inc.</td>
</tr>
<tr>
<td></td>
<td>Barbara and Jerry Freunditch</td>
</tr>
<tr>
<td></td>
<td>Larry and Marcia Greene</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Robert W. McAuley</td>
</tr>
<tr>
<td></td>
<td>Ms. Marian L. McKinney</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Eugene F. Murphy</td>
</tr>
<tr>
<td></td>
<td>Jane and John Nelson</td>
</tr>
<tr>
<td></td>
<td>David and Miriam Phalen and</td>
</tr>
<tr>
<td></td>
<td>The Grinberg Family Foundation</td>
</tr>
<tr>
<td></td>
<td>Judy and Pat Riordan</td>
</tr>
<tr>
<td></td>
<td>The Starr Foundation</td>
</tr>
<tr>
<td></td>
<td>Susan and Jeffrey Sussman</td>
</tr>
<tr>
<td></td>
<td>The David Tepper Charitable Foundation</td>
</tr>
<tr>
<td></td>
<td>Inc.</td>
</tr>
<tr>
<td></td>
<td>Andrea and Bruce Yablon</td>
</tr>
<tr>
<td><strong>$10,000 to $24,999</strong></td>
<td>Anonymous (1)</td>
</tr>
<tr>
<td></td>
<td>The David R. and Patricia D. Atkinson</td>
</tr>
<tr>
<td></td>
<td>Foundation</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Patrick Brown</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Clarence P. Cazalot, Jr.</td>
</tr>
<tr>
<td></td>
<td>The Leon and Toby Cooperman Family</td>
</tr>
<tr>
<td></td>
<td>Foundation</td>
</tr>
<tr>
<td></td>
<td>Mr. Joseph M. Ferraro</td>
</tr>
<tr>
<td></td>
<td>The Jill &amp; Mark Fishman Foundation</td>
</tr>
<tr>
<td></td>
<td>The Giles Family Foundation</td>
</tr>
<tr>
<td></td>
<td>David and Patricia Giuliani Family</td>
</tr>
<tr>
<td></td>
<td>Foundation</td>
</tr>
<tr>
<td></td>
<td>Mr. &amp; Mrs. Thomas E. Goldstone and</td>
</tr>
<tr>
<td></td>
<td>the Goldstone Fund</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Gary D. Hirsch</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Keith A. Hoegland</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Robert E. Kafafan</td>
</tr>
<tr>
<td></td>
<td>Barrie and Slen Kassan</td>
</tr>
<tr>
<td></td>
<td>Mr. Edward E. Matthews</td>
</tr>
<tr>
<td></td>
<td>Mr. David A. Messer</td>
</tr>
<tr>
<td></td>
<td>Mr. John D. Olson</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. John D. Ready</td>
</tr>
<tr>
<td></td>
<td>Donna and Paul Reinbolt</td>
</tr>
<tr>
<td></td>
<td>Marcia Robbins-Will, Ed.D</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Kevin Roche</td>
</tr>
<tr>
<td></td>
<td>Mr. Steven E. Rosen</td>
</tr>
<tr>
<td></td>
<td>Shari and James Rosenfeld</td>
</tr>
<tr>
<td></td>
<td>Targoff Family Foundation</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. David C. Wiener</td>
</tr>
<tr>
<td></td>
<td>Ms. Suzanne Williams</td>
</tr>
<tr>
<td></td>
<td>Dr. Adelaide W. Zabriskie</td>
</tr>
<tr>
<td><strong>$5,000 to $9,999</strong></td>
<td>Anonymous (4)</td>
</tr>
<tr>
<td></td>
<td>Mr. Oded Aboodi</td>
</tr>
<tr>
<td></td>
<td>Apfelbaum Family Foundation</td>
</tr>
<tr>
<td></td>
<td>David R. and Patricia D. Atkinson</td>
</tr>
<tr>
<td></td>
<td>Mr. John Ballantine</td>
</tr>
<tr>
<td></td>
<td>Ms. Janet L. Sikirica and</td>
</tr>
<tr>
<td></td>
<td>Mr. Gregory E. Barton</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Michael Beaury</td>
</tr>
<tr>
<td></td>
<td>Drs. Philip Behrman and Joan Delany</td>
</tr>
<tr>
<td></td>
<td>Ms. Maxa S. Berid, Esq.</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Ira W. Berman</td>
</tr>
<tr>
<td></td>
<td>Dr. Joseph R. Bertino</td>
</tr>
<tr>
<td></td>
<td>Mr. Robert P. Brennan, Jr.</td>
</tr>
<tr>
<td></td>
<td>Mr. Eric Cohen</td>
</tr>
<tr>
<td></td>
<td>Timothy A Cohn</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Denis F. Crenin</td>
</tr>
<tr>
<td></td>
<td>Mr. Jack O. Cunningham</td>
</tr>
<tr>
<td></td>
<td>The Ellen &amp; Gary Davis Foundation</td>
</tr>
<tr>
<td></td>
<td>Brian and Paula Dailey</td>
</tr>
<tr>
<td></td>
<td>Jonathan Dienshaus</td>
</tr>
<tr>
<td></td>
<td>The Ditzian Family</td>
</tr>
<tr>
<td></td>
<td>Gail and Larry Dobash</td>
</tr>
<tr>
<td></td>
<td>Joan K. Eigen</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Richard England</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Robert Feilbogen</td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Kevin J. Fennessey</td>
</tr>
<tr>
<td></td>
<td>Mr. Brian D. Fiala</td>
</tr>
<tr>
<td></td>
<td>Gantcher Family Foundation</td>
</tr>
<tr>
<td></td>
<td>Michael R. Gigueres</td>
</tr>
<tr>
<td></td>
<td>Family of John Grando</td>
</tr>
<tr>
<td></td>
<td>Mr. Geoff H. Grubbe</td>
</tr>
<tr>
<td></td>
<td>Ms. Christina Kaneen</td>
</tr>
<tr>
<td></td>
<td>Alexander and Wendy Haig</td>
</tr>
<tr>
<td></td>
<td>Leo and Stacey Helmers</td>
</tr>
</tbody>
</table>
For me and my family, our involvement with the Lymphoma Research Foundation has always been centered around doing whatever we can to help provide hope for the lymphoma community. Ten years ago, we decided to do that in the form of a bike ride, and now, the Lymphoma Research Ride has raised $4.7 million. For those considering involvement with LRF, I would say: do whatever you can—it’s amazing what that might turn into and what kind of impact you can have.”

— Lisa Taverna

Co-Founder, The Lymphoma Research Ride
Pictured above with Ride Participant, Ruthie Ash

Mr. Robert Horne
Mr. Jeffrey P. Hughes
Ms. Katherine Johnson
Mr. Robert Keith
Ellis and Anne Kern
Mr. Lawrence Kestin
Mr. Russell Kwiat
Mr. and Mrs. Martin Pollack
Pisani Family Foundation
Dr. and Mrs. Carlton Alexis
Marty and Lisa Assuncions
Roxy Ryan
Dr. and Mrs. Harvey L. Cole
Mr. and Mrs. John R. Barber
Mr. Kurt Belk and Ms. Joan Pearson
Frank Bireley
Mr. and Mrs. Roger Carter
Mr. and Mrs. Michael J. Byrne
Mr. and Mrs. Richard L. Chadakoff
Mr. and Mrs. Peter Chambers
Mr. and Mrs. David G. Chandler
Mr. and Mrs. Harvey L. Cole
Dr. and Mrs. Martin E. Corwin
David Divine
Mr. and Mrs. Richard Levine, MD
Pat Lloyd
Mr. and Mrs. Ronald Lorch
Ms. Jane A. Marotica
Kieran McAvoy
David and Jamie McLain
Dr. and Mrs. Vincent Zayas
Mr. and Mrs. Timothy Tipton
Mr. Paul Trapp
Ms. Liz Ulrich
Frank and Betty Vandermeer
Jeanette and Sherman Vogel
Scott Wald
Leah and Michael Weisberg
Weisfeld Family Foundation
Andrea and Robert Weiss
Susan and Benjamin Winter
Mrs. Penney Wolf
Karen and Barry Wolf
Mr. and Mrs. James J. Wong
Dr. and Mrs. Vincent Zayas

$1,000 to $2,499
Anonymous (9)
Ms. Liz Ulrich
Mr. and Mrs. Joseph M. Blair, Jr.
Susan and Benjamin Winter
Mrs. Penney Wolf
Karen and Barry Wolf
Mr. and Mrs. James J. Wong
Dr. and Mrs. Vincent Zayas

$2,500 to $4,999
Anonymous (2)
Dr. and Mrs. Martin Alexis
Marty and Lisa Assuncions
Ms. Jane L. Baker
Mr. and Mrs. Roger Carter
Mr. and Mrs. Harvey L. Cole
Dr. and Mrs. Martin E. Corwin
David Divine
Mrs. Laurie A Dripps
Doug Eckrote
Mr. and Mrs. Stephen Roger Ehrlich
Mary Clare Finney
Mr. and Mrs. David Freundlich
Vivian and Edward Friedman

Howard and Loren Friend
Robert and Linda Gardner
Ms. Shanda Geiser
Mr. and Mrs. Jeffrey Geller
Mr. and Mrs. Joe B. Gemmill
Mr. and Mrs. Michael Goldstein
The Goodman-Lipton Family Foundation
Green Family Foundation
Mrs. Eileen L. Greenland
Luke Griffin
Alex and Lisa Gribben
The Gruen Living Trust
Mrs. Joan L. Hauser
Mr. Forbes Hays
Tom Henderson & Paulette Maehara
Estate of Yvette Holder
Elliot Horowitz & Company, LLP
Mr. Jeffrey Iredell
Norman and Anne Jacobson
Daniel Kaplan
Mr. and Mrs. Michael Kramer
Milton & Henrietta Kushin Fund of the Hawaii Community Foundation
Mr. and Mrs. Peter T. Lawler
Mr. and Mrs. Herman Lebersfeld
Mr. and Mrs. Richard Levine, MD
Pat Lloyd
Mr. and Mrs. Ronald Lorch
Ms. Jane A. Marotica
Kieran McAvoy
David and Jamie McLain
Dr. and Mrs. Martin E. Corwin
David Divine
Mrs. Laurie A Dripps
Doug Eckrote
Mr. and Mrs. Stephen Roger Ehrlich
Mary Clare Finney
Mr. and Mrs. David Freundlich
Vivian and Edward Friedman

Mr. and Mrs. Michael Orlove
Mr. and Mrs. Alan P. Parney
Kathryn R. Pick
Ms. Ruth Pogany
The Robbins Family Foundation
Mr. Harvey Rose
Mrs. Phyllis Rosen
Don and Maria Runge/DMR Marketing, Inc.
Andrew Salzberg, MD
Mr. and Mrs. Ben Schneider
Joyce Schwartz
Mr. and Mrs. Alvin Segal
Mr. Alexander Silver
Lisa Taverna and Gary Ford
Mr. and Mrs. F. Duncan Terry
Gaylord and Diane Thorndogdard Family Fund
Mr. and Mrs. Timothy Tipton
Mr. Paul Trapp
Ms. Liz Ulrich
Frank and Betty Vandermeer
Jeanette and Sherman Vogel
Scott Wald
Leah and Michael Weisberg
Weisfeld Family Foundation
Andrea and Robert Weiss
Susan and Benjamin Winter
Mrs. Penney Wolf
Karen and Barry Wolf
Mr. and Mrs. James J. Wong
Dr. and Mrs. Vincent Zayas

$1,000 to $2,499
Anonymous (9)
Mr. Dale A. Adams
Dr. and Mrs. Richard Adicks
Mr. and Mrs. Nathan Adler
Norie and Larry Akman
Mr. and Mrs. Harold E. Akseirad
Morton Albert
Mrs. Linda P. Allen
Mr. and Ms. Aaron Amster
Mr. and Mrs. Alan P. Andert
Mr. Walter J. Andrews
Mr. and Mrs. John H. Atkinson
Mr. Philip Baily
Leonard Baxt
Michelle Beatolle
Ms. Helen Beck
Mr. and Mrs. Bruce Becker
Niel Beggy
Mr. and Mrs. Richard Bahr
Martin Beitzel
Mrs. Marjorie A. Berkley
Mr. and Mrs. Joseph M. Bertino
Kevin Beverly
Mr. and Mrs. Edward M. Blair, Jr.
Isabel Blanco Peruyera
Barbara and James Block
Don and Heidi Blumenthal
Mr. Warren Bedow
Sheri Borax
Mr. and Mrs. Dave Borgetti
Ms. and Mrs. Leonard Boxer
Mr. Donald Brady
Dr. Owen Brandt
Mr. Keith Britner
Mrs. Arlette W. Britton
Mr. Tom Brock
Allan and Bev Brodsky
Judith Bronsteen
Mr. and Mrs. Gregory G. Brown
The Bruening Foundation
Mr. Thomas Burke
Mrs. Sondra S. Busch
Ms. Elaine Cahn
Mrs. Betty Calderon
Mr. and Mrs. Wayne Canfield
Mr. and Mrs. Gary Carlson
Mrs. Gene Cartt
Dr. and Mrs. Wing C. (John) Chan
Mr. and Mrs. Robert M. Chase
From the moment I was diagnosed with lymphoma, I knew that I would do everything in my power to give back and help raise awareness on behalf of the Lymphoma Research Foundation. As both an Ambassador and a Walk participant, I’m committed to being a part of saving someone else’s life through my work with LRF.

— Erica Campbell
Hodgkin Survivor
LRF Ambassador and Captain, Team Our D’zire
The Lymphoma Research Foundation is helping to advance the research around some of the most innovative new areas of study; research that will help improve outcomes for patients like me going forward. — Geoff Grubbs
LRF Ambassador, CLL Survivor
| $500,000+ | Celgene Corporation  
Family Video Round It Up For Lymphoma Campaign  
Genentech |
|---|---|
| $250,000 to $499,999 | Bristol-Myers Squibb Company  
Gilead Sciences, Inc.  
Pharmaceuticals/ Janssen Biotech, Inc.  
Seattle Genetics, Inc.  
Takeda Oncology |
| $100,000 to $249,999 | AbbVie Inc.  
Teva Pharmaceuticals |
| $50,000 to $99,000 | Anonymous (1)  
Bayer  
Dragon Con, Inc.  
Jazz Pharmaceuticals, Inc.  
Sequenta  
Spectrum Pharmaceuticals, Inc. |
| $25,000 to $49,000 | Adaptive Biotechnologies  
Idera Pharmaceuticals, Inc.  
Merck & Co., Inc. |
| **Corporate Sponsors** | **Fiscal Year 2016 (July 1, 2015–June 30, 2016)** |

| $10,000 to $24,999 | Motorola Solutions Foundation  
Omnicom Group Inc.  
Parexel International LLC  
PJT Partners  
Sanofi-aventis U.S. Inc.  
The Fund for Blood & Cancer Research, Inc.  
Urovant Sciences Corporation |
|---|---|
| **$2,000 to $4,999** | Bank of America Charitable Foundation  
Be The Match  
BTG International Inc.  
Charity Golf Tournaments, Inc.  
Dalton and Finegold LLP  
Freyre Construction Foundation Medicine, Inc.  
Frescale Community Engagement Council  
GE Foundation  
KAF Financial Group  
Label LLC  
Northrop Grumman Corporation  
Polar Field Services, Inc.  
Seyfarth Shaw  
Tenaska, Inc.  
The Habit Restaurants, LLC  
Urovant Sciences Corporation GivePlus Program  
W.R. Berkley Corporation Charitable Foundation |
| **$1,000 to $2,499** | Ace Transcription Service  
Acerta Pharma  
Amazon Smile  
American Pest  
Ameriprise Financial  
Amgen Inc.  
Ariad Pharmaceuticals Inc.  
Asteria, LLC  
Baron Capital Foundation  
BB & T Corporation  
Bercom International, L.L.C.  
Biogen MA  
BP Foundation  
Bristol-Myers Squibb Foundation  
Calexico  
Capital Carpet & Flooring Specialists, Inc.  
Care 2 Fund at USLI Inc.  
Chubb and Son Federal Insurance Company  
City National Bank  
Clune Construction Company  
Community Realty & Development, Inc.  
Crag-Hallum Capital Group LLC  
Dingman’s Collision Center  
Eastern Bank Charitable Foundation  
Embrace Home Loans  
Environmental Test and Balance Co.  
EVDI Medical Imaging  
Exelon Foundation  
ExxonMobil Foundation, Inc. Matching Gifts Program  
Fresenius Kabi USA, LLC  
Genzyme Corporation  
HealthPlex Home Health Services  
Honeywell International Charity Matching  
I.B.E.W. Local Union #716  
JP Morgan Chase  
Keeper Security, Inc.  
Linde Engineering North America Inc.  
Macopin School Student Accounts Fund  
Medtronic  
Merck Foundation  
Messagebank, LLC  
Michael Best & Friedrich LLP  
MN-Minnesota Oncology Hematology  
Mr. and Mrs. Sidney Pokorny  
PKSA Karate-Northville, LLC  
Planned Asset Management  
Preferred Network Access, Inc  
Prime Surface Company, Inc.  
Prostrakan Inc.  
Quantitative Brokers LLC  
Randa Foundation  
RBC Capital Markets, LLC  
Retina Associates  
Salesmaster Associates Inc.  
Scientific Research Foundation  
St. Paul Lutheran Church  
State of Nebraska |
| **$500,000+** | SunTrust Bank  
Sygurus Systems  
Taylor Corporation  
TGI Friday’s  
The Nebraska Medical Center  
Tommy Scogs Foundation Inc  
Towers Watson  
Track Court Associates, LLC  
UnitedHealthCare Svs Inc.  
Vision Insurance Group, LLC  
West Deptford High School Girl’s Tennis  
WG & Associates Management and Development LLC  
Whirlpool Corporation  
Woodbury Fund |
Lymphoma has played a large role in our lives, but since we became involved with the Lymphoma Research Foundation, we are now able to play a larger role in working to create a future where it does not exist. The Team LRF initiative has been a true partner and there is no better feeling than helping others continue their lives and their love stories as we’ve been fortunate to continue ours.

— AJ Manas & Michelle Goldman
Team LRF Participants, Wedding for a Cause

<table>
<thead>
<tr>
<th>Fundraiser Name</th>
<th>Coordinator / Organizer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25,000-$100,000</td>
<td></td>
</tr>
<tr>
<td>Dragon Con Charity Fundraiser</td>
<td>Dragon Con</td>
</tr>
<tr>
<td>Irish Whisper Walk</td>
<td>Patti Kane</td>
</tr>
<tr>
<td>$10,000-$26,999</td>
<td></td>
</tr>
<tr>
<td>Annual Laps for Lymphoma Fundraiser</td>
<td>Grassfield High School</td>
</tr>
<tr>
<td>Harris Companies’ Charity Auction</td>
<td>Harris Companies</td>
</tr>
<tr>
<td>Kitchen &amp; Tasting Tour of St. James</td>
<td>Carol Deets</td>
</tr>
<tr>
<td>$5,000-$9,999</td>
<td></td>
</tr>
<tr>
<td>Art Exposition</td>
<td>Grace Scholafield</td>
</tr>
<tr>
<td>Climbing Kilimanjaro to Support LRF</td>
<td>Sandeep Uppal</td>
</tr>
<tr>
<td>Etiquette on the Runway-elite</td>
<td>Gigi Hatcher</td>
</tr>
<tr>
<td>Friends, Fondue and Fine Wines</td>
<td>Donna DeFronzo-Landsman</td>
</tr>
<tr>
<td>Fundraiser by Nick Stiassni</td>
<td>Nick Stiassni</td>
</tr>
<tr>
<td>Northeast Red Run</td>
<td>Anthony Ragucci</td>
</tr>
<tr>
<td>Rock-a-Thon Fundraiser</td>
<td>University of Kansas (Alpha Epsilon Pi)</td>
</tr>
<tr>
<td>$2,500-$6,499</td>
<td></td>
</tr>
<tr>
<td>2016 Truck Tour</td>
<td>The Habitat Restaurants, LLC</td>
</tr>
<tr>
<td>44th Annual Beard Shaving Event</td>
<td>Traphagen Financial Group</td>
</tr>
<tr>
<td>Annual Shad Miner Memorial Golf Tournament</td>
<td>Shanda Geiser</td>
</tr>
<tr>
<td>$2,500-$4,999 (Cont.)</td>
<td>Deerfield High School, Hard Rock Café-Atlanta, Kobe Harvey, Reston Masters Swim Team, Ryan Adkins, Thaise McCauley, Tom Goldstone, Carissa DaSilva</td>
</tr>
<tr>
<td>Fundraiser by Deerfield High School</td>
<td>Deerfield High School</td>
</tr>
<tr>
<td>Fundraiser by Hard Rock Café</td>
<td>Hard Rock Café-Atlanta</td>
</tr>
<tr>
<td>Fundraiser by Kobe Harvey</td>
<td>Kobe Harvey</td>
</tr>
<tr>
<td>Jim McDonnell Lake Swim</td>
<td>Reston Masters Swim Team</td>
</tr>
<tr>
<td>Kilometers for Cancer</td>
<td>Ryan Adkins</td>
</tr>
<tr>
<td>Live, Love, Cure 5K</td>
<td>Thaise McCauley</td>
</tr>
<tr>
<td>NYC Birthday “Biathlon”</td>
<td>Tom Goldstone</td>
</tr>
<tr>
<td>Team Kempe</td>
<td>Carissa DaSilva</td>
</tr>
<tr>
<td>$1,000-$2,499</td>
<td></td>
</tr>
<tr>
<td>Annual Blue Jay 5K Fundraiser</td>
<td>Robert Van Allen</td>
</tr>
<tr>
<td>Art In F Cancer Event</td>
<td>Teresa Tuley and Jack Chandler</td>
</tr>
<tr>
<td>Bald for Bruce</td>
<td>Colin Bishop</td>
</tr>
<tr>
<td>Bar Mitzvah Fundraiser</td>
<td>Jacob Morris</td>
</tr>
<tr>
<td>Fundraiser by Maxwell Mandell</td>
<td>Maxwell Mandell</td>
</tr>
<tr>
<td>Fundraiser by Nicole Harriman</td>
<td>Nicole Harriman</td>
</tr>
<tr>
<td>Rock to Cure Cancer</td>
<td>Donna Kelsey</td>
</tr>
<tr>
<td>Serve-A-Thon 2015 Fundraiser</td>
<td>West Deptford High</td>
</tr>
<tr>
<td>School Girl’s Tennis</td>
<td>Kimberly Meek</td>
</tr>
<tr>
<td>The Brian Meek Gold Memorial G. Ronald Shoemaker</td>
<td>G. Ronald Shoemaker</td>
</tr>
</tbody>
</table>
You can help the Lymphoma Research Foundation remain at the forefront of lymphoma research.

lymphoma.org/donate